Back to all papers

Deep learning-based segmentation and subtype prediction of renal cell carcinoma on contrast-enhanced CT.

July 14, 2026pubmed logopapers

Authors

Chen X,Xie Y,Huang Z,Xu B,Zhao F,Guo W,Mo G,Wu H,Peng P,Zhang Z,Zeng X,Zhu Y,Zhou J,Zhang Y,Tan W,Ping H,Zheng Z

Affiliations (8)

  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China. [email protected].
  • Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. [email protected].
  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China. [email protected].

Abstract

Accurate preoperative discrimination of renal cell carcinoma (RCC) subtypes is critical for treatment stratification. We aimed to develop and validate an automated deep learning system for simultaneous tumor segmentation and histopathological subtyping using multicenter contrast-enhanced CT (CECT) imaging. To this end, we constructed a two-stage system comprising separate segmentation and classification models. The segmentation model was trained on 245 scans from Nanfang Hospital and 210 from the KiTS19 public dataset. The classification model was developed and validated on a total of 750 patients, comprising an internal cohort from Nanfang Hospital (553 patients; 328 training, 112 validation, 113 testing) and two external validation cohorts: one from Beijing Tongren Hospital (n = 111) and another combined from two other centers (n = 86). The model demonstrated strong generalizability for discriminating clear cell RCC, with AUCs of 0.878 (internal validation), 0.892 (internal testing), 0.911 (external set Ⅰ), and 0.892 (external set Ⅱ). The model's computational efficiency reached 0.24 s per file and reduced FLOPs by four times compared to conventional 3D CNNs. This study validates the efficiency and clinical applicability of the YOLOv11 framework for RCC subtyping. Future efforts should integrate prospective data and multimodal imaging to enhance sensitivity for small lesions.

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.